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ABSTRACT 
 
Tuberous sclerosis complex (TSC) is an inherited genetic disorder caused by loss-of-
function mutations in either TSC1 or TSC2. Their respective gene products regulate the 
mechanistic target of rapamycin (mTOR) signaling pathway, which serves as an activator 
of cellular proliferation, metabolism, and cell survival. Orthologs of the TSC1 and TSC2 
genes exist in a wide range of organisms, including the commonly used and genetically 
tractable model eukaryote, Schizosaccharomyces pombe. To better understand the 
functional roles of S. pombe tsc1 and tsc2, I exploited recent advances in genetic interaction 
biology to identify and characterize genes that modulate the phenotypic effects of tsc1 and 
tsc2 gene deletions. As part of this work, I found ypa1 (encoding a peptidyl-prolyl cis-trans 
isomerase) and fft3 (encoding an ATP-dependent DNA helicase) to be negatively 
interacting with both tsc1 and tsc2. Importantly, while the loss of either ypa1 or fft3 in 
isolation had negligible effects on colony growth, their loss in tsc1Δ or tsc2Δ backgrounds 
resulted in significant growth impediments. Thus, the inhibition of either ypa1 or fft3 might 
represent an “Achilles’ heel” of cells defective in tsc1 or tsc2 function.  Lastly, I found that 
the negative interaction between ypa1 and tsc2 is conserved in mammalian cells. This 
suggests that the targeted inhibition of the orthologous gene product in humans epitomizes 
a novel therapeutic strategy to combat the TSC pathology.   
 
 
Keywords: tuberous sclerosis complex, fission yeast, gene buffering, genetic interaction, 
synthetic growth defect, mTOR pathway 
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CHAPTER I: INTRODUCTION 
 
1.1 Tuberous sclerosis complex 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder with an 
occurrence of approximately 1 in 8,000 live births (Rosner et al., 2004; Rosser et al., 2006). 
The disease causes benign tumors (known as hamartomas) in the brain, heart, kidneys, 
lungs, and eyes (Napolioni and Curatolo, 2008; Roux et al., 2004). Moreover, patients often 
suffer from a variety of skin conditions (e.g. hypomelanotic macules, facial angiofibromas, 
and forehead plaques) (Rosner et al., 2008). Neurological conditions such as autism, 
seizures, and learning disabilities are also common among affected individuals (Sampson, 
2009; Young and Povey, 1998). Figure 1-1 outlines the major clinical manifestations of 
the TSC pathology.  
Loss of heterozygosity in either TSC1 gene or the TSC2 gene is frequently 
associated with the TSC pathology in humans (Hengstschlӓger et al., 2001; Jones et al., 
1999). The TSC1 gene on chromosome 9q34 encodes hamartin, a 130-kDa hydrophilic 
protein containing a transmembrane domain and a coiled-coil domain that mediates 
protein-protein interactions (van Slegtenhorst et al., 1997; Jozwiak, 2006). The TSC2 gene 
on chromosome 16p13.3 encodes tuberin (The European Chromosome 16 Tuberous 
Sclerosis Consortium, 1993). Tuberin, a protein of approximately 200 kDa, forms an 
intracellular heterodimeric complex with hamartin to regulate downstream signaling 
(Jozwiak, 2006; Rosner et al., 2004). This process is regulated by tuberin phosphorylation 
which prevents both the degradation of tuberin by ubiquitination and the formation of 
homomeric hamartin complexes (Laplante and Sabatini, 2006; Rosner et al., 2004). 
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Figure 1-1: The multisystem pathogenesis of tuberous sclerosis complex. A range 
of tissues and organs are affected in those with TSC. Respective clinical conditions are 
noted in the blue boxes with percentages representing the corresponding occurrence in 
patients. Red stars (*) indicate clinical conditions that may arise from alternate TSC-
Rheb signaling networks. Reproduced from Neuman and Henske (2011) under the fair 
use provision of the Canadian Copyright Modernization Act (2012). 
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The hamartin-tuberin heterodimer is a key upstream component of the mechanistic 
target of rapamycin (mTOR) signaling pathway (Laplante and Sabatini, 2006). 
Importantly, homologs of the human TSC1 and TSC2 proteins are found across a range 
species, demonstrating that the signaling network is highly conserved (Figure 1-2) 
(Serfontein et al., 2011). Studies have also shown that the TSC1-TSC2 heterodimer act as 
a tumor suppressing complex to regulate cellular growth and proliferation (Mak and 
Yeung, 2004; Piedimonte et al., 2006; Roux et al., 2004). Interestingly, TSC-specific tumor 
progression follows the Knudson two-hit model of oncogenesis (i.e. where an inherited 
loss of function mutation in one allele and a sporadic loss of function mutation in the 
remaining allele lead to loss of heterozygosity at either the TSC1 or TSC2 locus) (Jozwiak 
et al., 2008; Mak and Yeung, 2004). 
 
1.2 The Akt-TSC1/2-mTOR signaling pathway 
The mTOR signaling pathway plays an important role in regulating cellular growth, 
proliferation, survival and metabolism (Franz and Weiss, 2012). mTOR is a 
serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K) related kinase 
family (Xu et al., 2014). mTOR is evolutionarily conserved and forms the catalytic core of 
two distinct multi-protein complexes, mTOR complex 1 (mTORC1), and mTOR complex 
2 (mTORC2) (Laplante and Sabatini, 2012); together, they promote cell growth in response 
to positive inputs such as nutrients and growth factors (Menon et al., 2014).  
The hamartin-tuberin heterodimer (TSC1-TSC2 complex) is a key upstream 
regulator of mTORC1 (Laplante and Sabatini, 2012). Tuberin possesses a catalytic GTPase 
activating protein (GAP) domain and works to negatively regulate the downstream Rheb 
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Figure 1-2: The conservation of hamartin and tuberin across species. Domain 
structure of the TSC1 (hamartin) and TSC2 (tuberin) proteins across species. Various 
colours indicate the relative level of homology to the orthologous human TSC proteins. 
The fission yeast Tsc1p and Tsc2p proteins are indicated with a red arrow. The coiled-
coil (CC) domains of the human TSC1 and TSC2, in addition to the TSC1 interaction 
domain (T1-ID) and GAP domain of TSC2 are conserved in S. pombe. The TSC2 
interaction domain on TSC1 (T2-ID) is not shown to be conserved, but this conclusion 
is not consistent between different alignments (Serfontein et al., 2011) and studies have 
shown Tsc1p-Tsc2p heterodimers exist in fission yeast (discussed later). Figure 
modified from Neuman and Henske (2011) under the fair use provision of the Canadian 
Copyright Modernization Act (2012).  
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protein (Manning and Cantley, 2003). Rheb (Ras homolog enriched in brain) is rendered 
inactive (GDP bound) by the negative GTPase activity of tuberin (Laplante and Sabatini, 
2012). Once growth factors and nutrients activate the insulin receptors (IR), PI3K can 
recruit phosphoinositide dependent protein kinase-1 (PDK1) which mediates serine 
phosphorylation of serine/threonine kinase Akt (Xu et al., 2014). Upon activation, Akt can 
phosphorylate and subsequently inhibit the TSC1-TSC2 complex; this results in the 
activation of Rheb (now GTP bound), which mediates the downstream activation of 
mTORC1 (Astrinidis and Henske, 2005; Benjamin and Hall, 2014; Dalle Pezze et al., 
2012). Aforementioned cell growth and proliferation is achieved upon further 
phosphorylation of several downstream effectors by mTORC1, leading to activation of the 
ribosomal s6 kinase-1 (p70S6K1) and inhibition of the 4E binding protein-1 (4E-BP1) 
(Manning and Cantley, 2003). 
Adding to the complexity of the Akt-TSC1/2-mTORC1 pathway is a negative 
feedback loop, initiated by p70S6K1-dependent phosphorylation and inhibition of IRs 
(Dalle Pezze et al., 2012). Furthermore, low energy levels, hypoxia, and cellular stress are 
also able to inactivate mTORC1 signaling (Benjamin and Hall, 2014). Growth factors can 
also modulate mTORC2 activation, however, the complex is geared towards cell survival, 
metabolism, and cytoskeletal organization (Dalle Pezze et al., 2012; Laplante and Sabatini, 
2012). Previous works suggest that mTORC2 activity is dependent on PI3K and is resistant 
to both rapamycin and the negative feedback loop that moderates mTORC1 activity (Dalle 
Pezze et al., 2012). Interestingly, mTORC2 activity is independent of Akt-TSC1/2 
regulation, suggesting a different regulatory mechanism for this signaling cascade (Dalle 
Pezze et al., 2012). Figure 1-3 provides a summary of the mTORC1 signaling pathway. 
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Figure 1-3: The Akt-TSC1/2-mTORC1 signaling cascade. Upon stimulation of the 
insulin receptors (IRs), the mTORC1 complex promotes increased levels of protein 
synthesis, inhibition of autophagy, cell growth and proliferation. Upstream kinases – 
PI3K and PDK1 modulate the phosphorylation and subsequent activation of Akt. Next, 
pAkt inactivate the TSC1-TSC2 heterodimeric complex, leading to an activated 
mTORC1. Activated mTORC1 phosphorylates and inhibits downstream 4E-BP1, 
which would otherwise repress protein translation. In contrast, mTORC1-mediated 
phosphorylation of S6K1 promotes ribosomal protein synthesis. The pathway is also 
regulated by several feedback mechanisms (not shown).  
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1.3 Fission yeast as a model system to study the TSC pathology  
The fission yeast Schizosaccharomyces pombe is a unicellular organism commonly used 
in the field of eukaryotic cellular and molecular biology. It is genetically tractable and is 
often used to examine fundamental cellular processes such as transcription, translation, 
cell-cycle control, DNA damage and repair, signaling pathways, and epigenetics (Forsburg, 
2005; Hoffman et al., 2015).  
The S. pombe genome has been fully sequenced to reveal ~ 5000 protein-coding 
genes (ORFs) distributed among three chromosomes (Wood et al., 2002). Among the 
proteins encoded by the S. pombe genome, a subset of 172 proteins share close homology 
with human disease proteins (Wood et al., 2002). Moreover, the S. pombe laboratory strains 
can be diploid or haploid – carrying only a single set of chromosomes (Forsburg and Rhind, 
2006). This is crucial in examining genes of interest in disease models, as mutant alleles 
can be screened for loss-of-function phenotypes when compared to the wild type alleles 
(Hoffman et al., 2015). Altogether, the ease of manipulation and the genomic conservation 
of S. pombe makes it a powerful tool to study human disease. 
Orthologs of human TSC1 and TSC2 genes have been identified in fission yeast 
(named tsc1 and tsc2, respectively) (Serfontein et al., 2011; Sun et al., 2013). In addition, 
several components of the mTOR signaling pathway are also conserved in S. pombe 
(Figure 1-4) (Aspuria et al., 2007; Wullschleger et al., 2006). Functional Tsc1p and Tsc2p 
are crucial in nutrient uptake and the regulation of biosynthetic pathways (Mak and Yeung, 
2004). Moreover, the fission yeast Tsc1p-Tsc2p heterodimer regulates a downstream Rheb 
protein (ortholog of mammalian Rheb) through its GAP activity (Aspuria et al., 2007). As 
in mammalian cells, Rheb in a GTP-bound state can then activate the S. pombe Tor proteins  
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Figure 1-3: The TSC/Rheb/mTOR signaling pathway is well conserved in S. 
pombe. Orthologs of human TSC1 and TSC2, along with several components of the 
mTOR signaling pathway is conserved in fission yeast. TSC1 and TSC2 orthologs do 
not exist in the budding yeast Saccharomyces cerevisiae. Furthermore, S. pombe Tor2p 
forms a complex (with Mip1p and Wat1p) akin to the mammalian mTORC1 to regulate 
cell cycle and cellular growth. The Tor2p is activated by the upstream Rheb protein 
which is regulated by the GAP activity of Tsc1p-Tsc2p heterodimer. However, unlike 
in mammalian cells (Akt phospohorylation of TSC1-TSC2), the upstream regulatory 
mechanisms of the Tsc1p-Tsc2p complex in fission yeast remain unknown. Proteins 
with the same color share substantial structural homology across species (i.e. 
mammalian Raptor, fission yeast Mip1p, and budding yeast Kog1p). Reproduced from 
Aspuria et al. (2007) under the fair use provision of the Canadian Copyright 
Modernization Act (2012). 
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(orthologs of mTOR) (Wullschleger et al., 2006). However, in S. pombe, the Tor2p forms 
the TOR1 complex which interacts in a mTORC1-like manner to regulate protein 
translation, metabolism and nutrient dependent cellular growth and proliferation (Gonzalez 
and Rallis, 2017; Matsuo et al., 2007; Rallis et al., 2014). Nonetheless, S. pombe is a great 
adjunct in examining the mechanisms of mammalian TOR signaling and, as such, is 
important in the understanding of the TSC pathology.                                 
 
1.4 Gene buffering and genetic interactions 
Loss-of-function mutations are crucial in contrasting mutant phenotypes with their 
respective wild-type phenotypes. In nature, however, these phenotypes are often 
quantitative and the mechanisms underlying a disease are multifaceted (Hartman IV et al., 
2001; Horn et al., 2011). Gene buffering is a phenomena which provides robustness against 
genetic mutations leading to phenotypic variation and complexity (Kitami and Nadeau, 
2002). Classically, gene buffering occurs between genes within the same biological 
pathway or in parallel pathways with complementary cellular functions (Hartman IV et al., 
2001). However, genes in ‘redundant’ pathways of unrelated biochemical functions can 
also buffer one another (Kitami and Nadeau, 2002).  
Unpredicted phenotypic outcomes resulting from gene buffering between genes are 
coined as genetic interactions (Costanzo et al., 2011). Recent advances in genome-wide 
synthetic genetic array (SGA) analysis have allowed for high-throughput identification of 
these interactions (Collins et al., 2007; Costanzo et al., 2010). Furthermore, digenic 
(between two genes) interactions can be scored by comparing the fitness of the double 
mutants – typically colony growth size, against the fitness of the respective single mutants 
10 
 
(Baryshnikova et al., 2010; Costanzo et al., 2011; Frost et al., 2012). A digenic genetic 
interaction is categorized as being either ‘positive’ or ‘negative’ in nature (Baryshnikova 
et al., 2010). Positive interactions occur when the observed double mutant fitness is greater 
than expected (Costanzo et al., 2011). In contrast, negative interactions occur when double 
mutant fitness is less than expected (Baryshnikova et al., 2010). Figure 1-5 summarizes the 
key concepts of gene buffering.  
Included in the set of negative interactions are cases of synthetic lethality/sickness 
(Dixon et al., 2008). In these cases, the simultaneous loss of two gene products results in 
death or severe growth defects, but the loss of either gene-product individually has little or 
no effect (Baryshnikova et al., 2013; Costanzo et al., 2011). In tumor cells, synthetic 
growth defects may also arise between genes and small molecules as a mode of drug 
discovery; this is because, a typical tumor cell accumulates genetic mutations and 
morphological changes, exposing the tumor cell to vulnerabilities that a normal cell would 
not face (Nijman, 2011). Thus, protein products of genes that are synthetic lethal to tumor-
forming genetic mutations are ideal candidates for therapeutic targets (Kaelin, 2005). 
Hartwell et al. (1997) forged this concept of selectively targeting tumor cells to uncover 
prospective anticancer drugs. The group used yeast gene deletion mutants to screen 
pharmaceutical inhibitors (Kaelin, 2005). However, technological advances in gene 
knockdowns using short interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), 
and CRISPR/Cas9-mediated complete gene knockouts through guide RNAs (gRNAs) have 
made it possible to lead high-throughput screens for synthetic lethality across genomes 
(Beijersbergen et al., 2017). Figure 1-6 highlights the fundamental strategies used with 
respect to the exploitation of synthetic lethality in uncovering novel cancer therapeutics.  
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Figure 1-5: The buffering of genetic variation. (A) Phenotypic variation due to gene 
A is modulated by gene B, and vice versa. The dotted circle (upper panel) highlights the 
capacity of gene A to “buffer” variation in gene B.  This is to say, in the presence of 
functional gene A, gene B can accumulate genetic variation without affecting its activity 
(lower panel).  Simultaneous mutations in both genes A and B lead to an abrogation of 
genetic buffering and a lethal phenotype (red arrow). Modified from Hartman IV et al. 
(2001) under the fair use provision of the Canadian Copyright Modernization Act (2012). 
(B) Negative genetic interactions arise when the double mutant (AB) fitness/phenotype 
is impaired beyond the expected. The resultant synthetic growth defect can be classified 
as synthetic sick or synthetic lethal. Modified from Costanzo et al.  (2011) under the fair 
use provision of the Canadian Copyright Modernization Act (2012).    
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Figure 1-6: Applying synthetic lethality to cancer therapeutics. (A) Standalone 
mutations to either gene A or gene B is tolerated (viable phenotype). However, 
simultaneous mutation of both genes causes lethality. Reproduced from Kaelin W 
(2005) under the fair use provision of the Canadian Copyright Modernization Act 
(2012). (B) The tumor cells have acquired a genetic mutation in gene A. Since gene A 
and B are synthetic lethal, inhibition of gene B or the gene B protein product with an 
Anti-B agent (gene knockout or pharmacological inhibitor) will lead to tumor-specific 
cell death. Awt = wild-type gene A, and Am = mutant gene A. Reproduced from 
Beijerbergen et al. (2016) under the fair use provision of the Canadian Copyright 
Modernization Act (2012). 
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Fortunately, these strategies have led to the discovery of numerous drug targets across a 
variety of cancer models (Beijersbergen et al., 2017; Costa-Cabral et al., 2016; Pourdehnad 
et al., 2013). 
 
1.5 Genetics to therapeutics: rationale for my study 
Inhibition of mTOR signaling with rapamycin has previously shown therapeutic benefits 
in treating TSC patients; but, rapamycin-independent pathways are also thought to play a 
role in the manifestation of the disorder (Franz and Weiss, 2012; Kenerson et al., 2005). 
Furthermore, resistance to rapamycin treatment has been observed in rat models of the 
disease (Kenerson et al., 2005; Mak and Yeung 2004). Interestingly, combination therapies 
involving rapamycin and secondary drugs have shown potency in limiting tumorigenesis 
(Li et al., 2007; Perera et al., 2009). Hence, the identification of alternate ‘drugable’ targets 
for novel and/or combination therapies may provide more effective options for the 
treatment of the TSC pathology (Neuman and Henske, 2011). 
Fortunately, recent advances with respect to genetic buffering have provided novel 
avenues of therapeutic exploration. These avenues rely on the creation of genetic 
interaction maps, known as genetic interactomes (Costanzo et al., 2011). Genome-wide 
interactomes and subsequent analyses in budding yeast, Caenorhabditis elegans, and 
mouse fibroblasts, have shown that these interactions can influence a variety of phenotypes 
associated with complex genetic phenomenon, including human disorders (Baryshnikova 
et al., 2013). Of particular interest to TSC researchers are negative interactor genes that 
display synthetic growth defect in conjunction with the TSC1 or TSC2 loss of 
heterozygosity. Inhibiting such genes would presumably impede the growth of 
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homozygous tumor cells (bearing two mutant copies of the affected TSC gene) while 
leaving phenotypically normal heterozygous cells unaffected (carrying only the mutant 
germline copy) (Beijersbergen et al., 2017; Kaelin, 2005). Interestingly, a recent screen for 
synthetic growth defects in mammalian cells led to the identification of candidate drug 
targets for the TSC pathology (Housden et al., 2015). Therefore, these negative interactors 
might represent an “Achilles’ heel” of tumor cells deficient in hamartin/tuberin function 
and, therefore, are ideal targets for therapeutic intervention in TSC patients. 
Ryan et al. (2012) recently constructed a large-scale genetic interactome for the 
fission yeast S. pombe. The group has provided an opportunity to test the idea that genetic 
buffering relationships can indeed be exploited to identify novel drug targets. Using the 
genetically tractable fission yeast as a model, my study aimed to utilize advances in genetic 
interaction biology to elucidate the cellular and molecular mechanisms of TSC 
pathogenesis. In brief, a series of experiments were conducted to address the following 
areas of interest: (i) the validation of putative negative interactors of fission yeast tsc1 and 
tsc2, (ii) the identification of sites within these interactors that may be amenable to 
pharmacological inhibition, (iii) investigation of the fission yeast tsc2 alleles bearing 
orthologous mutations to clinical TSC patients, and (iv) the conservation of S. pombe 
synthetic interactions in mammalian cells. Altogether, my study sought to identify novel 
targets for inhibitory drugs, to be used alone (or in combination with rapamycin) to obstruct 
tumor-specific growth in individuals affected by the TSC pathology. 
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1.6 Hypothesis and predictions 
I hypothesize that perturbation of the fission yeast negative interactor genes will alter the 
cellular growth of the tsc1Δ and tsc2Δ mutants as well as the tsc2 strains bearing 
orthologous clinical mutations (i.e. loss of function mutations). Additionally, I predict that 
complete gene deletions of the validated interactors, or the site-directed mutagenesis within 
their catalytic sites will result in the impediment of colony growth in tsc1Δ and tsc2Δ 
mutant backgrounds. In contrast, I predict that the effect of the mutated interactors in 
fission yeast cells lacking loss of function mutations of tsc1 and tsc2 will be negligible.  
Moreover, I hypothesize that the synthetic interactions in S. pombe will be 
conserved in mammalian cells. I predict that RNAi-mediated knockdowns of target genes 
(orthologous to the validated fission yeast negative interactors) in TSC2-deficient mouse 
fibroblasts will result in cell-specific lethality. I expect such treatments to reduce cellular 
viability in fibroblasts that match the molecular context of the TSC tumor cells.      
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CHAPTER II: MATERIALS AND METHODS 
 
2.1 Yeast strains and culture conditions 
Fission yeast strains were cultured as indicated in YES, SPA, or EMM media supplemented 
with a combination of adenine, histidine, leucine, and uracil (Forsburg and Rhind, 2006). 
Gene deletion strains used in the study were obtained from Bioneer Corporation 
(https://us.bioneer.com/products/spombe/Library-overview.aspx). Bioneer employs 
homologous recombination (HR) to replace an ORF of interest with a deletion cassette 
(Kim et al., 2010). The deletion cassettes are comprised of a kanMX4 selection marker, 
which confers resistance to the antibiotic, G418, along with flanking tag sequences and 
two fragments homologous to the 5’ and 3’ flanking region of the target ORF (Figure 2-1).  
Several S. pombe strains bearing site-directed mutations were also constructed. The 
relevant DNA sequences bearing the desired mutations were synthesized by GenScript® 
and cloned into the S. pombe integration vector, pJK210. The integration constructs were 
linearized and then transformed into a wild-type strain using the lithium acetate protocol 
(Gietz et al., 1992). Viable colonies in uracil-deprived EMM-agar media were assessed for 
integration at the desired locus through colony PCR (Figure 2-2). The products of the 
colony PCR reactions were analyzed on 1% agarose gels made with tris-acetic EDTA 
(TAE) buffer and stained with RedSafe™ solution (iNtRON Biotechnology). The 
genotypes of all S. pombe strains used in this study are listed in Table 2-1.  
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Figure 2-1: Methodology used to construct the Bioneer haploid gene deletion 
mutant set. Deletion cassettes bearing i) the kanMX4 marker, ii) flanking tag 
sequences, and iii) sites of homology to the fission yeast gene of interest were integrated 
into wild-type S. pombe cells via homologous recombination (Kim et al., 2010). 
Colonies bearing the construct were selected on YES-agar plates supplemented with 
G418.      
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Figure 2-2: Methodology used to generate ypa1 and fft3 mutant strains via site-
directed mutagenesis. The relevant mutant DNA sequences (e.g. to generate the fft3-
K418R mutant) were designed and ordered from GenScript®. The synthesized 
sequences arrived cloned into the pUC57 vector. (1) The mutant sequence is freed from 
the pUC57 vector by restriction digestion (digestion site indicated by vertical grey 
lines).  (2) The restriction fragment is cloned into the S. pombe integrating vector 
pJK210 via enzymatic ligation. (3) The vector is linearized via restriction digestion 
(digestion site indicated by a vertical grey line). (4, 5) The linearized vector is 
transformed into S. pombe where it integrates at the native locus via homologous 
recombination to generate mutant colonies on uracil-deprived EMM media. (6, 7) 
Integration at the correct locus is verified by colony PCR (2678 bp amplification).  
Vertical red bars represent the site-directed mutation of Lysine418 (K418R). Bright teal 
arrows indicate the primer set used to verify fft3-K418R integration into the wild-type 
fission yeast genome. 
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Table 2-1. S. pombe strains used in the study.  
 
 
 
 
 
 
 
Strain Genotype Source 
JK484 ura4-D18 leu1-32 ade6-210 his3-D1 h- JK collection 
ED666 ura4-D18 leu1-32 ade6-210 h+ JK collection 
UC7 ura4-D18 h+ JK collection 
UC8 ura4-D18 h- JK collection 
TSC13 tsc1::ura4 ura4-D18  h+ Bioneer 
TSC14 tsc2::ura4 ura4-D18  h+ Bioneer 
TSC17 tsc1::ura4 ura4-D18  h- JK collection 
TSC18 tsc2::ura4 ura4-D18  h- JK collection 
TSC83 ypa1::kanMX4 h+ Bioneer 
TSC86 fft3::kanMX4 h+ Bioneer 
P17-81 cdk11::kanMX4 h+ Bioneer 
AR1 ypa1-D212G::ura4+ This study 
AR2 ypa1-V208D::ura4+ This study 
AR3 fft3∆791-872::ura4+ This study 
AR4 fft3-K418R::ura4+ This study 
TSC154 tsc2::tsc2-R1296P h- JK collection 
NGE1 lip2::kanMX4 h+ Bioneer 
NGE2 aap1::kanMX4 h+ Bioneer 
NGE3 atg14::kanMX4 h+ Bioneer 
NGE4 spac25a8.03c::kanMX4 h+ Bioneer 
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2.2 Generation of S. pombe double mutants 
Fission yeast double mutants were generated using standard genetic techniques (Forsburg 
and Rhind, 2006). Briefly, cells of each single mutant strain were mixed on SPA-agar 
media and incubated at 30°C as mating process is temperature-sensitive. SPA media is 
nitrogen-deprived and induces mating and sporulation, resulting in tetrads, each comprised 
of four haploid spores. Once a given cross was plated on a fresh YES-agar plate, a Zeiss 
Axioskop 40 microscope was utilized to dissect the individual tetrad. Following a brief 
incubation period at 30°C (to break down tetrad walls), the haploid spores were separated. 
The individual spores formed colonies within 48 hours and viable double mutants were 
isolated on YES-agar plates containing G418 antibiotic and/or EMM media lacking uracil. 
 
2.3 Colony growth analysis 
The S. pombe double mutant strains were streaked onto YES-agar plates along with the 
respective single gene deletion mutants and a wild-type control. Next, the Zeiss Axioskop 
40 microscope was utilized to separate individual cells and arrange them across the YES-
agar media (three trials consisting a maximum of four technical replicates from each 
strain). The plates were incubated at 30°C for five days to assay colony growth. Images 
were taken every 24 hours using an Alpha Innotech Flurochem SP imaging system. Colony 
sizes were measured using ImageJ (Abràmoff et al., 2004). 
 
2.4 Cell culture and reagents 
Tsc2+/+p53-/- (P118) and Tsc2-/-p53-/- (P119) mouse embryonic fibroblasts (MEFs) were 
kindly provided by Dr. DJ Kwiatkowski, Brigham and Women’s Hospital, Harvard 
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Medical School, Boston, MA, USA. These MEFs are connective tissue cells that are 
precursors to extracellular matrix and collagen, harvested from mouse embryos age 
embryonic day10.5 (E10.5) (Zhang et al., 2003). The p53 knockout (p53-/-) was necessary 
to prevent premature senescence of the Tsc2-/- MEFs (Zhang et al., 2003). All cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin (pen-strep). 
The cells were grown at 37°C in a humidified atmosphere of 5% CO2 and 95% air up to 
70-90% confluency before sub-culturing. P118 and P119 cell cultures were observed and 
imaged using an inverted Leica DM IL LED microscope in integrated modulation contrast 
(IMC) mode. DMEM and FBS were purchased from Life Technologies. Pen-strep, DPBS, 
and TrypLE were obtained from Gibco. Trypan Blue for cell counting was purchased from 
Sigma-Aldrich. Falcon T-25 and T-75 animal cell culture flasks were used to passage and 
maintain the MEFs.  
 
2.5 Genotyping the mouse embryonic fibroblasts 
The Tsc2-/- line was previously generated by inserting a neomycin cassette into exon 3 of 
the Tsc2 gene (Figure 2-3) (Onda et al., 1999). To confirm the knockout, genomic DNA 
(gDNA) was isolated from the P118 and P119 MEFs using DNAzol® (Molecular Research 
Centre, Inc.). Subsequent PCR reactions were performed using oligonucleotides H162, 
H163, and H164 (Table 2.2). PCR products were analyzed on 1.7% agarose gel made with 
TAE buffer and stained with SYBR® safe (Invitrogen).             
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Figure 2-3: Generation of the Tsc2-/- allele in mouse embryonic fibroblasts. A 
neomycin cassette was inserted into exon 3 of the mouse Tsc2 gene (Onda et al., 1999). 
This construct disrupted Tsc2 coding sequence (CDS). Coloured arrows represent the 
primer binding sites of the oligonucleotides designed to confirm the absence/presence 
of the neomycin cassette in the P118 and P119 MEFs.   
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2.6 Transfections 
siGENOME SMARTpool siRNAs targeting Ppp2r4 and Smarcad1 mouse genes were 
purchased from Dharmacon™. In addition, a scrambled siRNA targeting no known mouse  
gene was also obtained. A working concentration of 10 nM was used for each siRNA for 
transfections. All transfections were done using the Lipofectamine® RNAiMAX 
transfection reagent (Invitrogen) according to the manufacturer’s protocol. Cells were 
grown to 40-60% confluency in media lacking pen-strep. Transfections were then 
performed in either 24-well or 96-well plates. Cells were then incubated at 37°C with 5% 
CO2 for 48 hours before further assays were performed. 
 
2.7 RNA extraction and cDNA synthesis 
Cells were transfected with siRNAs in 24-well plates and incubated for 48 hours. Total 
RNA was then isolated from transfected cells using TRIzol™ Reagent (Invitrogen) 
according to the manufacturer’s protocol. SuperScript™ III First-Strand Synthesis 
Supermix for qRT-PCR kit (Invitrogen) was used to generate respective cDNA from 1 µg 
of total RNA. Subsequent PCR reactions were performed with AR3F and AR3R, AR4F 
and AR4R, or AR5F and AR5R to confirm gene knockdowns (Table 2-2). PCR products 
were then analyzed on 1.7% agarose gel made with TAE buffer and stained with SYBR® 
Safe (Invitrogen). 
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Table 2-2. Oligonucleotides used in the study. Complete forward (F) and reverse (R) 
primer sequences along with the size of the PCR products are shown. 
 
 
 
 
 
 
 
 
 
Primers Gene Sequence (5’ to 3’) Amplicon Size 
AR1 ypa1 F: TACAGCGTCTCAATATTGCATCTG 
 
R: TCCTATGTTGTGTGGAATTGTGAG 
 
1024 bp 
AR2 fft3 F: TCCCTCATTTACTTCCTCTGCTAA 
 
R: TCCTATGTTGTGTGGAATTGTGAG  
 
2426 bp (fft3∆791-
872) and 2678 bp 
(fft3-K418R) 
AR3 Gapdh F: TGGCCTTCCGTGTTCCTAC 
 
R: GAGTTGCTGTTGAAGTCGCA 
 
178 bp 
AR4 Ppp2r4 F: ACCCCTCCAACTACTCAGAAC 
 
R: CACCTATCCAGCGTATCAAGAAG 
 
215 bp 
AR5 Smarcad1 F: TGTTTGCGGAAGATCAAGACG 
 
R: CAGAGTCCTCTACGGCTTTCTTA 
 
201 bp 
H162/ 
H163 
Tsc2 F: ACCCACCTCCTCAAGCTTCT 
 
R:  AGACTGCCTTGGGAAAAGCG 
 
198 bp 
H162/ 
H164 
Tsc2 F:  ACCCACCTCCTCAAGCTTCT 
 
R: TTGGTTTACAGGGGAAATGC 
 
96 bp 
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2.8 Cell viability assay 
The viability of siRNA-transfected cells was evaluated using the CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega). The assay mobilizes ATP in the viable cells 
to emit stable luminescent signals that can be measured. The results from the assay 
estimates metabolically active cells and can be analyzed to determine differences in cell 
viability among various groups. P118 and P119 MEFs were first seeded at 0.25 x 106 
cells/mL in 96-well plates (100 µL/well). Cells were then transfected with the relevant 
siRNAs within a 24 hours incubation period.  After a transfection period of 48 hours, 100 
µL of the CellTiter-Glo reagent was directly added to the individual wells. The Infinite 
M1000 (Tecan) monochromator based microplate reader was utilized to quantify the 
“glow-type” luminescent signals in the 96-well plates.       
 
2.9 Data analysis 
Pairwise comparisons of colony sizes were performed among the wild-type, single mutant 
and the double mutant S. pombe strains. Statistically significant differences were 
determined by the non-parametric Wilcoxon Rank Sum test in R v3.2.2 after applying the 
Benjamini and Hochberg multiple-testing correction (Benjamini and Hochberg, 1995).  
Statistically significant differences between control and siRNA treatment groups in 
cell viability assays were determined by the non-parametric Friedman test in GraphPad 
Prism v7.0.2 adjusted with the Benjamini and Hochberg multiple-testing correction 
(Benjamini and Hochberg, 1995). Graphical illustrations were produced using the 
GraphPad Prism v7.0.2 software.  
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CHAPTER III: RESULTS 
 
3.1 Validation of candidate negative interactors 
Recent high-throughput efforts in S. pombe have resulted in the creation of a genetic 
interaction map (http://interactome-cmp.ucsf.edu/pombe2012/modules/search.html; Ryan 
et al., 2012).  Analysis of this publicly available database revealed a subset of thirteen genes 
that are negative interactors of both tsc1 and tsc2. This small group of genes displayed 
strong synthetic growth defects (SGA scores of less than -4) when deleted in combination 
with tsc1 or tsc2 gene deletions. Of these genes, only ypa1 and fft3 were selected for 
validation and detailed analysis as they have clear orthologs in a variety of developmentally 
complex eukaryotes, including humans (Costelloe et al., 2012; De Virgilio and Loewith, 
2006; Durand-Dubief et al., 2012; Goyal and Simanis, 2012; Neves-Costa et al., 2009). 
Interestingly, a genome wide screen in Drosophila spp. also identified the Pitslre gene as 
a negative interactor of the fruit fly genes – Tsc1 and Tsc2 (Housden et al., 2015). As this 
gene is conserved in humans (known as CDK11) as well as fission yeast (known as cdk11), 
it was also included in this study. 
Crosses of ypa1∆, fft3∆, and cdk11∆ mutants with either tsc1∆ or tsc2∆ S. pombe 
strains were performed to generate the respective double mutants. Colony growth analysis 
was then performed to monitor the growth of individual yeast cells over a period of five 
days (see Figure 3-1, for an example of ypa1 mutants). Comparisons were made among 
cells from the following groups – wild-type S. pombe, single gene deletion mutants, and 
the corresponding double mutants. 
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Figure 3-1: Representative example of YES-agar media plate used in colony 
growth analysis. Several S. pombe strains were plated in an YES-agar media plate. 
Growth was monitored for 5 days. Images were taken at every 24 hours interval. Red 
box highlights the tsc1∆ypa1∆ double mutant that exhibits severe growth defect 
compared to the respective single mutant strains – wild type, tsc1∆, and ypa1∆. 
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The colony growth analysis revealed that ypa1∆ demonstrated strong synthetic 
growth defects with both tsc1∆ and tsc2∆ mutants (Figure 3-2). Although, both tsc1∆ and 
ypa1∆ single mutant strains were hindered in their ability to grow, the tsc1∆ypa1∆ double 
mutant colony sizes were significantly perturbed (p < 0.0005 at day 5, for all pairwise 
comparisons with double mutants; Figure 3-2B). The tsc2∆ypa1∆ double mutants also 
followed a similar trend of growth impediment (p < 0.0005 at day 5, for all pairwise 
comparisons with double mutants; Figure 3-2D). In addition, fft3∆ mutant demonstrated 
strong negative interaction with both tsc1∆ and tsc2∆ mutants (p < 0.0005 at day 5, for all 
pairwise comparisons with double mutants; Figure 3-3 B, D). The resultant colony growth 
defects of the double mutants (tsc1∆fft3∆ and tsc2∆fft3∆) followed similar growth pattern 
to that of the tsc1∆ypa1∆ and tsc2∆ypa1∆ double mutants (Figures 3-2 A, C & 3-3 A, C). 
In contrast, the cdk11 gene deletion mutants did not exhibit any clear growth 
impediment. The tsc1∆cdk11∆ and tsc2∆cdk11∆ double mutant colonies were significantly 
smaller than the wild-type colonies (p < 0.0005 at day 5, for all pairwise comparisons with 
double mutants; Figure 3-4 B, D). However, the double mutant colonies demonstrated 
similar growth to tsc1∆, tsc2∆, and cdk11∆ single mutants (p > 0.05 at day 5, for all 
pairwise comparisons with double mutants; Figure 3-4 A, C). Altogether, ypa1 and fft3 
were confirmed as negative interactors of both tsc1 and tsc2. As such, the two fission yeast 
genes were carried forward for further detailed analysis. 
 
3.2 Additional synthetic interaction screens 
Recent work in S. cerevisiae has indicated that negative interactions can be falsely 
annotated due to neighboring gene effects (NGEs); whereby, the deletion of a gene can  
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Figure 3-2: tsc1∆ypa1∆ and tsc2∆ypa1∆ double mutants exhibit reduced colony 
growth relative to the respective single mutants. (A) Heat map describing average 
colony size (arbitrary units) in wild-type, tsc1Δ, ypa1Δ, and tsc1Δypa1Δ mutants over 
five days (n = 12, for all groups). (B) Box and whisker plot describing average colony 
size (arbitrary units) in wild-type, tsc1Δ, ypa1Δ, and tsc1Δypa1Δ mutants at day 5. (C) 
Heat map describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1Δ, 
and tsc2Δypa1Δ mutants over five days (n = 12, for all groups). (D) Box and whisker 
plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1Δ, and 
tsc2Δypa1Δ mutants at day 5. Lower case letters represent significant differences (if 
any) among the groups.   
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Figure 3-3: tsc1∆fft3∆ and tsc2∆fft3∆ double mutants display decreased colony 
growth relative to the respective single mutants. (A) Heat map describing average 
colony size (arbitrary units) in wild-type, tsc1Δ, fft3Δ, and tsc1Δfft3Δ mutants over five 
days (n = 12, for all groups). (B) Box and whisker plot describing average colony size 
(arbitrary units) in wild-type, tsc1Δ, fft3Δ, and tsc1Δfft3Δ mutants at day 5. (C) Heat 
map describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3Δ, and 
tsc2Δfft3Δ mutants over five days (n = 12, for all groups). (D) Box and whisker plot 
describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3Δ, and tsc2Δfft3Δ 
mutants at day 5. Lower case letters represent significant differences (if any) among the 
groups.   
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Figure 3-4: tsc1∆cdk11∆ and tsc21∆cdk11∆ double mutants do not exhibit differences in 
colony growth relative to the respective single mutants. (A) Heat map describing average 
colony size (arbitrary units) in wild-type, tsc1Δ, cdk11Δ, and tsc1Δcdk11Δ mutants over five 
days (n = 11, 12, 12, and 12, respectively). (B) Box and whisker plot describing average colony 
size (arbitrary units) in wild-type, tsc1Δ, cdk11Δ, and tsc1Δcdk11Δ mutants at day 5. (C) Heat 
map describing average colony size (arbitrary units) in wild-type, tsc2Δ, cdk11Δ, and 
tsc2Δcdk11Δ mutants over five days (n = 12, for all groups). (D) Box and whisker plot 
describing average colony size (arbitrary units) in wild-type, tsc2Δ, cdk11Δ, and tsc2Δypa1Δ 
mutants at day 5. Lower case letters represent significant differences (if any) among the groups.   
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affect the adjacent genes along a genome leading to improper annotation of negative 
interactions (Atias et al., 2015). In fact, NGE is relatively extensive with a ~10% rate, 
which can distort large-scale genetic interactomes (Ben-Shitrit et al., 2012). As such, 
inappropriate recordings of genetic interactions require correction and subsequent 
replacement with new and correct mapping of the relevant interactions. I examined 
potential NGE effects on the observed data using the following mutants – lip2∆, aap1∆, 
atg14∆, and spac25a8.03c∆. These genes are immediately adjacent to the previously 
validated tsc1 and tsc2 negative interactors, ypa1 and fft3. The data demonstrated that the 
corresponding double mutants of the adjacent gene deletion mutants do not exhibit any 
significant growth defects compared to the single mutants (p > 0.05 at day 5, for all pairwise 
comparisons with double mutants; Figure 3-5 & 3-6). These results provide strong evidence 
that the synthetic interactions mapped in this study are not influenced by NGEs. 
 
3.3 Identification of catalytic sites within the interactors 
The determination of specific functional domains within Ypa1p and Fft3p can help identify 
sites that may be amenable to pharmacological inhibitors. Based on current literature and 
bioinformatic analyses, three domains were identified – one within the Ypa1p (PPIase 
domain) (Jordens et al., 2006; Jouvet et al., 2011; Leulliot et al., 2006), and two within the 
Fft3p (ATPase domain and helicase domain) (Byeon et al., 2013; Chen et al., 2012; Eapen 
et al., 2012; Steglich et al., 2015). An online based multi-alignment tool, Clustal Omega 
(Sievers et al., 2011), was used to verify the conservation of these putative sites across 
several eukaryotes (Figure 3-7). Using this information, several integration constructs were 
designed to create S. pombe strains expressing ypa1-D212G, ypa1-V208D, fft3-K418R, and 
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Figure 3-5: Double mutants of lip2∆ and aap1∆ (adjacent to ypa1) do not exhibit 
colony growth defects relative to the respective single mutants. (A, C) Heat map 
describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ, lip2Δ, 
tsc1Δlip2Δ, and tsc2Δlip2Δ mutants over five days (n = 12, 11, 12, 12, 11, and 11, 
respectively). (B, D) Box and whisker plot describing average colony size (arbitrary 
units) in wild-type, tsc1Δ, tsc2Δ, lip2Δ, tsc1Δlip2Δ, and tsc2Δlip2Δ mutants at day 5. 
(E, G) Heat map describing average colony size (arbitrary units) in wild-type, tsc1Δ, 
tsc2Δ, aap1Δ, tsc1Δaap1Δ, and tsc2Δaap1Δ mutants over five days (n = 12, 12, 12, 12, 
10, and 12, respectively). (F, H) Box and whisker plot describing average colony size 
(arbitrary units) in wild-type, tsc1Δ, tsc2Δ, aap1Δ, tsc1Δaap1Δ, and tsc2Δaap1Δ 
mutants at day 5. Lower case letters represent significant differences (if any) among the 
groups.   
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Figure 3-6: Double mutants of atg14∆ and spac25a8.03c∆ (adjacent to fft3) do not 
exhibit colony growth defects relative to the respective single mutants. (A, C) Heat 
map describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ, atg14Δ, 
tsc1Δatg14Δ, and tsc2Δatg14Δ mutants over five days (n = 12, 11, 12, 11, 8, and 11, 
respectively). (B, D) Box and whisker plot describing average colony size (arbitrary 
units) in wild-type, tsc1Δ, tsc2Δ, atg14Δ, tsc1Δatg14Δ, and tsc2Δatg14Δ mutants at day 
5. (E, G) Heat map describing average colony size (arbitrary units) in wild-type, tsc1Δ, 
tsc2Δ, spac25a8.03cΔ, tsc1Δspac25a8.03cΔ, and tsc2Δspac25a8.03cΔ mutants over 
five days (n = 12, 11, 12, 11, 12, and 12, respectively). (F, H) Box and whisker plot 
describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ, 
spac25a8.03cΔ, tsc1Δspac25a8.03cΔ, and tsc2Δ spac25a8.03cΔ mutants at day 5. 
Lower case letters represent significant differences (if any) among the groups.   
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Figure 3-7: Multiple sequence alignments comparing Ypa1p and Fft3p to their 
human and mouse orthologs. A Highly conserved PPIase domain is present within 
Ypa1p (purple box). The Fft3p contains a highly conserved ATPase domain (purple 
arrow) and a helicase domain (*not shown). The pink letter boxes denote the site-
directed mutagenesis of fission yeast strains performed in this study. Sp, 
Schizosaccharomyces pombe; Mm, Mus musculus; Hs, Homo sapiens.     
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fft3Δ791-874 (see Materials and Methods). The mutant strains were then crossed to either 
tsc1∆ or tsc2∆ strains to generate the respective double mutants. 
The ypa1 site-directed double mutants (tsc1∆ypa1-D212G, tsc2∆ypa1-D212G, 
tsc1∆ypa1-V208D, and tsc2∆ypa1-V208D) did not show any significant differences in 
colony growth compared to their respective tsc1∆ and tsc2∆ mutant strains (p > 0.05 for 
all pairwise comparisons at day 5; Figure 3-8 & Figure 3-9). Likewise, the helicase-deleted 
fft3 double mutants also followed the growth trends of the tsc1∆ and tsc2∆ mutants (p > 
0.05 for the pairwise comparisons at day 5; Figure 3-10). In contrast, fft3-K418R double 
mutants did show a significant impediment in colony growth compared to the wild-type 
and respective single mutant strains (p < 0.05 for all pairwise comparisons at day 5; Figure 
3-11). However, the synthetic growth defects witnessed in these double mutants were not 
as prominent as the growth defects previously seen in the fft3∆ double mutants. 
Nonetheless, the result suggest that the ATPase domain within the Fft3p may be 
pharmacologically targeted in cells with loss of function mutations in tsc1 and tsc2.  
 
3.4 Assaying clinically orthologous mutations in S. pombe 
As part of an ongoing project in the lab, strains expressing tsc2 alleles bearing mutations 
orthologous to those found clinically have been created (G296E, R927W, N1191K, 
N1199S, P1223L, R1296P) (Figure 3-12). These tsc2 alleles were examined to screen any 
negative interactions with fft3 and ypa1. Of the six mentioned tsc2 mutants, only tsc2-
R1296P mutants were found to negatively interact with both ypa1 and fft3 (p < 0.05 for all 
double mutant pairwise comparisons at day 5; Figure 3-13 A to D; data not shown for the 
other five mutants). Furthermore, the growth defects exhibited by the tsc2-R1296P ypa1∆  
40 
 
 
 
 
A B
` 
C D 
Figure 3-8: tsc1∆ypa1-D212G and tsc2∆ypa1-D212G double mutants do not exhibit 
reduced colony growth relative to the respective single mutants. (A) Heat map 
describing average colony size (arbitrary units) in wild-type, tsc1Δ, ypa1-D212G, and 
tsc1Δypa1-D212G mutants over five days (n = 12, 12, 11, and 12, respectively). (B) 
Box and whisker plot describing average colony size (arbitrary units) in wild-type, 
tsc1Δ, ypa1-D212G, and tsc1Δypa1-D212G mutants at day 5. (C) Heat map describing 
average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-D212G, and tsc2Δypa1-
D212G mutants over five days (n = 12, 12, 12, and 11, respectively). (D) Box and 
whisker plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-
D212G, and tsc2Δypa1-D212G mutants at day 5. Lower case letters represent 
significant differences (if any) among the groups.   
 
41 
 
 
 
 
A B 
C D 
Figure 3-9: tsc1∆ypa1-V208D and tsc2∆ypa1-V208D double mutants do not exhibit 
reduced colony growth relative to the respective single mutants. (A) Heat map 
describing average colony size (arbitrary units) in wild-type, tsc1Δ, ypa1-V208D, and 
tsc1Δypa1-V208D mutants over five days (n = 11, 12, 12, and 11, respectively). (B) 
Box and whisker plot describing average colony size (arbitrary units) in wild-type, 
tsc1Δ, ypa1-V208D, and tsc1Δypa1-V208D mutants at day 5. (C) Heat map describing 
average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-V208D, and tsc2Δypa1-
V208D mutants over five days (n = 12, 12, 10, and 11, respectively). (D) Box and 
whisker plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-
V208D, and tsc2Δypa1-V208D mutants at day 5. Lower case letters represent significant 
differences (if any) among the groups.   
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Figure 3-10: tsc1∆fft3∆791-872 and tsc2∆fft3∆791-872 double mutants do not 
exhibit reduced colony growth relative to the respective single mutants. (A) Heat 
map describing average colony size (arbitrary units) in wild-type, tsc1Δ, fft3∆791-872 
and tsc1Δfft3∆791-872 mutants over five days (n = 12, 12, 12, and 11, respectively). 
(B) Box and whisker plot describing average colony size (arbitrary units) in wild-type, 
tsc1Δ, fft3∆791-872, and tsc1Δfft3∆791-872 mutants at day 5. (C) Heat map describing 
average colony size (arbitrary units) in wild-type, tsc2Δ, fft3∆791-872, and 
tsc2Δfft3∆791-872 mutants over five days (n = 12, for all groups). (D) Box and whisker 
plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3∆791-872, 
and tsc2Δfft3∆791-872 mutants at day 5. Lower case letters represent significant 
differences (if any) among the groups.   
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Figure 3-11: tsc1∆fft3-K418R and tsc2∆fft3-K418R double mutants demonstrate 
reduced colony growth relative to the respective single mutants. (A) Heat map 
describing average colony size (arbitrary units) in wild-type, tsc1Δ, fft3-K418R, and 
tsc1Δfft3-K418R mutants over five days (n = 12, 11, 12, and 11, respectively). (B) Box 
and whisker plot describing average colony size (arbitrary units) in wild-type, tsc1Δ, 
fft3-K418R, and tsc1Δfft3-K418R mutants at day 5. (C) Heat map describing average 
colony size (arbitrary units) in wild-type, tsc2Δ, fft3-K418R, and tsc2Δfft3-K418R 
mutants over five days (n = 12, 11, 12, and 12, respectively). (D) Box and whisker plot 
describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3-K418R, and 
tsc2Δfft3-K418R mutants at day 5. Lower case letters represent significant differences 
(if any) among the groups.   
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Figure 3-12: Clustal Omega alignment of human TSC2 and fission yeast Tsc2p. 
Colored bars indicate domains of the human TSC2 protein that are conserved in S. 
pombe Tsc2p. Pink labelled boxes indicate fission yeast Tsc2p mutations that are 
orthologous to the corresponding disease-causing human TSC2 alleles. Sp, 
Schizosaccharomyces pombe; Hs, Homo sapiens.    
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and tsc2-R1296P fft3∆ double mutants were highly comparable to those of the tsc2∆ypa1∆ 
and tsc2∆fft3∆ double mutants (Figure 3-13 E, F). Thus, the observed interactions between 
tsc2 and ypa1 or fft3 are indeed allele specific.  This demonstrates that the loss of fft3 or 
ypa1 activity is not necessarily detrimental to growth in all cells exhibiting deficiencies in 
hamartin or tuberin function.  Instead, the results imply that the genetic interactions depend 
on the subtleties of Tsc1p/Tsc2p molecular function in an allele specific manner (see 
Discussion). 
 
3.5 Genotyping the mouse embryonic cell lines 
The validated interactors from the initial screen in S. pombe have clear orthologs in 
organisms ranging from yeast to humans. Thus, Ppp2r4 (ortholog of ypa1) and Smarcad1 
(ortholog of fft3) were tested to see if the negative interactions were conserved in more 
developmentally complex eukaryotes.  To this end, Tsc2+/+p53-/- and Tsc2-/-p53-/- mouse 
embryonic fibroblasts (MEFs) were obtained from Dr. DJ Kwiatkowski (Onda et al., 1999).  
After the initial thawing process, the P118 (Tsc2+/+p53-/-) and P119 (Tsc2-/-p53-/-) 
MEFs were sub-cultured twice before genotyping. Cells show typical fibroblastic 
morphology (Figure 3-14 A, B) as reported earlier (Onda et al., 1999). For each type of 
cells, gDNA was isolated and two simultaneous PCR reactions were performed using one 
of either H163 (within exon 3 of Tsc2) or H164 primers (within the neomycin cassette 
insert) in combination with the H162 primer (within exon 3 of Tsc2). Results show an 
expected 198 base pairs (bp) PCR amplificon for the P118 MEFs (PCR product of 
H163/H162), with no PCR product from H164/H162 (Figure 3-14 C). In contrast, there 
was a H164/H162-96 bp PCR product amplified for the P119 MEFs, with no PCR product  
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Figure 3-13: tsc2-R1296P ypa1∆ and tsc2-R1296P fft3∆ double mutants 
demonstrate reduced colony growth relative to the respective single mutants. (A) 
Heat map describing average colony size (arbitrary units) in wild-type, tsc2-R1296P, 
ypa1∆, and tsc2-R1296P ypa1∆ mutants over five days (n = 8, 8, 8, and 6, respectively). 
(B) Box and whisker plot describing average colony size (arbitrary units) in wild-type, 
tsc2-R1296P, ypa1∆, and tsc2-R1296P ypa1∆ mutants at day 5. (C) Heat map 
describing average colony size (arbitrary units) in wild-type, tsc2-R1296P, fft3∆, and 
tsc2-R1296P fft3∆ mutants over five days (n = 10, for all groups). (D) Box and whisker 
plot describing average colony size (arbitrary units) in wild-type, tsc2-R1296P, fft3∆, 
and tsc2-R1296P fft3∆ mutants at day 5. (E) tsc2-R1296P ypa1∆ and tsc2∆ypa1∆ 
double mutants suffer from similar growth perturbations. (F) tsc2-R1296P fft3∆ and 
tsc2∆fft3∆ double mutants exhibit similar growth impediment. Lower case letters 
represent significant differences (if any) among the groups.   
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Figure 3-14: Genotyping of the P118 and P119 MEF cell lines. (A) Microscopic 
view of the P118 MEFs at passage 2, objective 20X, scale bar – 100 µm (light 
microscopy). (B) Microscopic view of the P119 MEFs at passage 3, objective 20X, 
scale bar – 100 µm (light microscopy). (C) The indicated primers (combination of 
H162, H163, and H164) were used to PCR amplify genomic DNA from P118 and P119 
cells. The resulting amplicons were run on a 1.7% agarose gel to confirm the 
presence/absence of the neomycin cassette. 
A B 
C 
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from H163/H162 (Figure 3-14 C). The data confirmed that exon 3 of the Tsc2 gene is 
disrupted in the P119 cells, and thus induced a loss of function mutation. Hence, the P119 
MEFs provided a powerful tool for examining the synthetic interactions (identified in 
fission yeast) in more developmentally complex eukaryotes.    
 
3.6 Conservation of negative interactions in mouse embryonic fibroblasts 
The validated interactors from the initial screen in S. pombe have clear orthologs in 
developmentally complex eukaryotes, including mice and humans. Thus, Ppp2r4 (ortholog 
of ypa1) and Smarcad1 (ortholog of fft3) were tested to see if the negative interactions were 
conserved in the MEFs. Both P118 and P119 cells were transfected for 48 hours with 10 
µM siRNAs. Treatments with scrambled siRNA had no effects on the mRNA expressions 
of Smarcad1 and Ppp2r4 compared to the untreated samples. However, siRNAs 
specifically targeting the mRNA of Smarcad1 or Ppp2r4 greatly abolished their respective 
gene expressions (Figure 3-15). 
Upon validation of siRNA-mediated knockdowns, cell viability was assayed to 
determine synthetic interactions between Tsc2 and Ppp2r4 or Smarcad1. CellTiter-Glo 
assays were utilized to monitor the number of viable cells based on the presence of ATP. 
The reagent from the assay generated stable luminescent signals which were read through 
a luminometer to approximate cell viability. The wild-type P118 and Tsc2-deficient P119 
cells were transfected with either Ppp2r4 or Smarcad1 siRNAs. Results showed that both 
Ppp2r4 and Smarcad1 siRNA treatments had no effects on cell viability of the P118 MEFs 
(p > 0.05 for all pairwise comparisons with control group; Figure 3-16 A). Interestingly, 
the Ppp2r4 siRNA-mediated knockdown in the Tsc2-deficient P119 MEFs demonstrated a 
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significant reduction in the cell viability (~ 26% reduction, p = 0.01 for the pairwise 
comparison with control group; Figure 3-16 B). This supports the hypothesis that negative 
interaction between tsc2 and ypa1 witnessed in fission yeast may indeed be conserved in 
mammals. Smarcad1, however, did not show a similar trend of negative interaction with 
Tsc2 (p = 0.22 for pairwise comparison with control group; Figure 3-16 B). 
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Figure 3-15: siRNA knockdown at 48 hours. (A) Smarcad1 and Ppp2r4 gene 
expression in P118 cells is abolished upon siRNA treatments (lane 6 of each image). 
(B) Smarcad1 and Ppp2r4 gene expression in P119 cells is abolished upon siRNA 
treatments (lane 6 of each image).  The housekeeping gene, Gapdh was used as a 
control. U = untreated cells, Scr = negative control siRNA targeting no known mouse 
genes, siRNA = corresponding siRNA used to knockdown gene of interest.   
A 
B 
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Figure 3-16: Cell viability of MEFs 48 hours following siRNA treatment. (A) 
Relative cell viability of P118 cells treated with a scrambled siRNA control or siRNAs 
targeting Ppp2r4, or Smarcad1 (n = 3, for all groups). (B)  Relative cell viability of 
P119 cells treated with a scrambled siRNA control or siRNAs targeting Ppp2r4, or 
Smarcad1 (n = 3, for all groups).  Statistical analyses were performed using the 
Friedman test in GraphPad Prism v7.0.2. **p = 0.01; n.s. denotes a statistically 
insignificant difference.  
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CHAPTER IV: DISCUSSION 
 
The primary objective of this study was to explore the genetic interaction network 
underlying tuberous sclerosis complex. This was done in part to elucidate the mechanism 
of the TSC pathogenesis; but, also to identify prospective drug targets for novel therapeutic 
strategies. The study looked to utilize large-scale genetic buffering relationships 
discovered in fission yeast to reveal negative interactors of both tsc1 and tsc2. In addition, 
RNAi knockdowns in mammalian cells were used to further assess any promising 
candidates screened through the fission yeast genetic interactions. 
 
4.1 Overview of the fission yeast genetic interactome 
Genetic interactions are vital in the translation of genotypic information to phenotypic 
consequences. These networks are known to be important in understanding complex 
human diseases and may play a role in the mystery of ‘missing heritability’ (Horn et al., 
2011; Zuk et al., 2012). Analyses in model systems support the notion that genetic 
interactions between alleles can inflate variation and phenotypic outcomes (Horn et al., 
2011). Unlike protein-protein interactions, genetic interactions are not limited to physical 
association between their respective encoded proteins (Ryan et al., 2012). In fact, only ~1% 
of the genetic interactions overlap with corresponding protein-protein interactions (Boone 
et al., 2007; Tong et al., 2004). Instead, genetic interactomes provide invaluable 
information with respect to functional attributes of genes and often reveal the role of gene 
products involved in functionally related pathways (Boone et al., 2007; Ryan et al., 2012).  
Most genes exhibit few genetic interactions, while a few genes (‘hubs’) are highly 
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connected in the interaction map and are more likely to be functionally important (Tong et 
al., 2004). 
The budding yeast S. cerevisiae was first analyzed to generate large-scale genetic 
interaction networks (Costanzo et al., 2010). However, such analysis in the distantly related 
S. pombe was limited to small scale investigations of specific pathways and cellular 
processes (Roguev et al., 2007; Roguev et al., 2008). Nonetheless, a quantitative and 
genome-wide S. pombe genetic interactome was recently mapped, encompassing ~50% of 
the genome with ~1.6 million generated digenic interactions (Ryan et al., 2012). In 
addition, the group annotated numerous functions to previously uncharacterized genes. The 
generation of this powerful dataset provided an opportunity to examine prospective 
synthetic interactions concerning tuberous sclerosis complex.    
 
4.2 Characterization of the validated negative interactors 
Fission yeast Tsc1p and Tsc2p act in pathways akin to their respective homologs in humans 
(TSC1 and TSC2). This study aimed to exploit recent work (Housden et al., 2015; Ryan et 
al., 2012) to identify negative interactor genes of both tsc1 and tsc2 in fission yeast. The 
colony growth assays validated ypa1 and fft3, but not cdk11, as negative interactors of tsc1 
and tsc2 (Figure 3-2 to 3-4). The data were in accordance with the prediction that complete 
gene deletions of ypa1 and fft3 in tsc1∆ and tsc2∆ backgrounds would result in severe 
reduction of colony growth size.    
Fission yeast ypa1 encodes the protein – phosphotyrosyl phosphatase activator 
(PTPA, also known as Ypa1p). Little is known about fission yeast PTPA, except that it 
regulates the activity of serine/threonine protein phosphatase 2A (PP2A) (Goyal and 
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Simanis, 2012). Likewise, the budding yeast PTPA (encoded by rrd1) regulate the catalytic 
activity of PP2A, which is a known associate of the TOR pathway (Poschmann et al., 2011; 
Van Hoof et al., 2000; Zheng and Jiang, 2005). Mutants bearing rrd1Δ have several 
morphological defects including irregular progression through G1/S transition of the cell 
cycle (Jordens et al., 2006; Van Hoof et al., 2001). Interestingly, researchers have 
discovered that DNA-dependent protein kinase (DNA-PK) activation by PP2A is required 
for the repair of double stranded breaks (DSBs) through non-homologous end joining 
(NHEJ) (Li et al., 2013) and the process is known to occur primarily in the G1 phase (Chen 
et al., 2011). Additionally, PTPA association with RNA polymerase II (RNAPII) is crucial 
in the regulation of stress-responsive genes (Poschmann et al., 2011). In rrd1Δ mutants, 
transcriptional control may be lost due to RNAPII disassociation from the coding 
sequences (Sen et al., 2014). Taken together, budding yeast PTPA may act to regulate the 
TOR pathways and the NHEJ pathway of DNA repair indirectly through PP2A activity, 
and work directly to activate RNAPII mediated transcription of stress-responsive genes. 
Whether the S. pombe PTPA participates in DNA damage repair and the regulation of the 
cell cycle in similar ways requires more comprehensive analyses. 
The Fft3 protein is a Swi/Snf2 family ATP-dependent chromatin remodeler that is 
greatly conserved across many eukaryotes (Steglich et al., 2015). Previous work has 
demonstrated that Fft3p is essential in maintaining the heterochromatin structure of the 
centromeric and sub-telomeric regions and plays a role in the regulation of the overall 
nuclear organization (Steglich et al., 2015; Strålfors et al., 2011). In S. pombe, fft3∆ results 
in euchromatin formation leading to incorrect histone modifications and mis-regulation of 
gene expression (Strålfors et al., 2011). Thus, Fft3p may be crucial in key cellular processes 
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such as transcription, DNA repair and DNA replication (Steglich et al., 2015). 
Interestingly, Fft3p orthologs – Fun30 in S. cerevisiae and SMARCAD1 in humans, are 
known to aid in DNA end resection of DSBs via G2 cell cycle homologous recombination 
(HR) (Chen et al., 2012; Costelloe et al., 2012; Eapen et al., 2012). Inability to successfully 
repair DSBs compromises genome integrity and leads to prolonged G1/G2 checkpoint 
arrest which often results in apoptosis (Massagué, 2004). Fun30 can increase the rate of 
the 5’-to-3’ DNA resection and deactivate the G2/M DNA damage checkpoint arrest 
(Eapen et al., 2012). This is done at the chromatin level, where Fun30 (as well as the human 
homolog SMARCAD1) can relax the tight histone-DNA interactions in nucleosomes 
adjacent to DSBs (Chen et al., 2012; Costelloe et al., 2012). In fission yeast, however, the 
precise mechanism of the Fft3p role in the DNA damage repair has not been explored.    
As discussed earlier, genetic interactions rarely implicate physically associated 
gene products (Tong et al., 2004). Furthermore, only a small subset of strong negative 
interactions amount to interactions in ‘within-pathway’ complexes (Costanzo et al., 2011). 
In S. cerevisiae, most synthetic lethal interactions, albeit rare, occur between genes with 
similar cellular functions (Tong et al., 2004). Fission yeast hamartin-tuberin heterodimeric 
complex have been shown to play a role in the regulation of nutrient uptake, cellular growth 
and stress response (Aspuria et al., 2007; Mak and Yeung, 2004); and the role of Ypa1p, 
Fft3p and their homologs has been discussed above. Thus, it is highly likely that the strong 
negative genetic interactions exhibited among ypa1, fft3, and tsc1/2 do not correspond to 
physical protein-protein interactions. Instead, the results in this study suggest that the genes 
participate in ‘between-pathway’ genetic interactions. These interactions often occur 
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among functionally related genes in complementary biological pathways (Boone et al., 
2017).  
In S. pombe, the role of Ypa1p and Fft3p suggests that cellular processes such as 
transcription and DNA repair may contribute to the Tsc1p-Tsc2p controlled TOR pathways 
which regulates cellular growth, proliferation and stress-response. Interestingly, Ypa1p is 
known to regulate the activity of PP2A (Goyal and Simanis, 2012) and its budding yeast 
ortholog is associated with the TOR pathways (Poschmann et al., 2011; Van Hoof et al., 
2000; Zheng and Jiang, 2005). Thus, the fission yeast PTPA (Ypa1p) may yet be implicated 
in the TOR pathways and the functional complementarity among the protein products of 
the genes (ypa1, fft3, tsc1, and tsc2) could provide an explanation for the strong negative 
interactions validated in this study. 
 Interestingly, however, ypa1 and fft3 did not demonstrate any synthetic 
interactions between the genes (data not shown). This finding supports the notion that 
Ypa1p and Fft3p are involved in different pathways that can impinge on shared function 
affecting cellular growth. Hence, although negative genetic interactions are frequent 
between genes within the same cellular pathway or pathways that are closely linked 
(Baryshnikova et al., 2010), it may not be a requirement. In fact, ‘hub’ genes can interact 
with numerous genes making them essential to a wide range of cellular processes (Boone 
et al., 2007). Therefore, these genes are crucial in modulating phenotypic variation and 
complexity. Whether tsc1 and tsc2 can be considered as ‘hub’ genes remain to be 
determined. Here, the findings suggest that the fission yeast cells with tumor-like molecular 
context (loss of functional tsc1 and tsc2) can be selectively targeted to inhibit growth. 
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Hence, Ypa1p and Fft3p provide promising candidates for further investigation and are 
prospective drug targets in TSC therapeutics. 
4.3 Applying the concept of synthetic chemical-genetic interactions 
A traditional strategy for anticancer drug discovery is to assay inhibitory compounds for 
their ability to selectively target cells that mimic the molecular alterations of tumor cells 
(Hartwell et al., 1997). Using the digenic negative interaction dataset, specific 
pharmacological inhibitors can be screened for lethality emulating novel drug-gene 
synthetic interactions (Beijersbergen et al., 2017; Boone et al., 2007; Kaelin, 2005; Nijman, 
2011). Inhibition of the catalytic domains in Ypa1p and Fft3p by chemical treatments in 
combination with tsc1 or tsc2 loss of function mutations, therefore, should result in cellular 
growth defects. In principle, this may allow for selective targeting of tumor cells (lacking 
functional TSC1 and TSC2) using synthetic lethal chemical-genetic interactions (Boone et 
al., 2007). Thus, it was important to identify sites that may be amenable to chemical 
inhibition within the fission yeast Ypa1p and Fft3p. 
The study first examined the highly conserved PPIase domain of the Ypa1p 
(PTPA). The PTPA PPIase domain is well conserved across eukaryotes including the 
budding yeast (Chao et al., 2006, Jordens et al., 2006; Leulliot et al., 2006). Proteomic 
analyses have shown that PTPA mutations in budding yeast aspartate213 and valine209 sites 
within the catalytic core compromised binding with PP2A (Chao et al., 2006; Leulliot et 
al., 2006). Also, mutations in these sites resulted in the loss of the PTPA phosphatase 
activity and abolished ATP-dependent activation of PP2A (Guo et al., 2014). Their 
orthologous S. pombe strains – ypa1-D212G and ypa-V208D, however, did not seem to 
suffer from a similar loss of function, as the double mutants with tsc1∆ and tsc2∆ did not 
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exhibit expected growth perturbations (Figures 3-8 and 3-9). These results suggest one of 
two possibilities.  First, that unlike mutations in the S. cerevisiae PTPA, these subtle 
missense mutations do not cause significant conformational changes in the fission yeast 
PTPA and abolish the PPIase activity, or second, that the observed synthetic growth defect 
results from the loss-of-function of a PPIase independent activity. Interestingly, S. 
cerevisiae mutants bearing complete deletion of the catalytic PPIase domain have been 
shown to drastically impair the activation of PP2A (Jordens et al., 2006). The work in my 
study aimed to reciprocate this deletion in S. pombe, but was unable to generate any viable 
strain (data not shown).                
In contrast, the ATPase dead fft3-K418R mutants demonstrated synthetic growth 
defects with both tsc1 and tsc2 as predicted (Figure 3-11). In fission yeast, the ATPase 
activity of Fft3p has been shown to maintain subtelomeric and centromeric 
heterochromatin structures (Steglich et al., 2015; Strålfors et al., 2011). Moreover, the 
ATPase domain is important to the function of many other SWI/SNF chromatin remodelers 
(Hargreaves and Crabtree, 2011), and is highly conserved across eukaryotes (Figure 3-7). 
Previous studies in S. cerevisiae showed that ATPase dead Fun30 mutants suffered G2 cell 
cycle arrest due to unsuccessful 5’ to 3’ DNA end resection of DSBs (Chen et al., 2012; 
Eapen et al., 2012). Likewise, siRNA knockdowns of SMARCAD1 (Fft3p and Fun30 
homolog in humans) resulted in accumulation of cells with DNA damage and impaired 
DNA repair mechanisms (Costelloe et al., 2012). Furthermore, in budding yeasts, the 
Fun30 helicase domain is thought to be important in the remodeling of nucleosomes and 
efficient DNA end resection (Awad et al., 2010; Chen et al., 2012). However, the helicase-
deleted fission yeast mutants (fft3∆791-872) did not display synthetic growth defects with 
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either tsc1 or tsc2 (Figure 3-10). Here, the results suggest that the loss of the ATPase 
activity of Fft3p through a site-directed mutation (K418R) is primarily responsible for the 
observed negative interaction. Thus, the data suggest a prospective site of pharmacological 
inhibition within Fft3p that might recapitulate the negative interaction between fft3 and 
tsc1/tsc2.   
 
4.4 Investigation of disease-causing clinical mutations in S. pombe 
Although mutations in TSC1 and TSC2 can be inherited as autosomal dominant traits (in 
familial cases with at least one affected parent), most cases of TSC are sporadic (~65% 
without an affected parent) (Narayanan, 2003). TSC2 mutations are significantly 
overrepresented among sporadic cases of the disease (Jones et al., 1999; Napolioni and 
Curatolo, 2008). Furthermore, clinical phenotypes arising from patients with TSC2 
mutations are more severe (Franz and Weiss, 2012; Mak and Yeung, 2004; Neuman and 
Henske, 2011). Thus, the study sought to investigate clinical TSC2 mutations. Six S. pombe 
strains with tsc2 alleles bearing orthologous TSC2 missense mutations were examined, to 
test for synthetic interactions with the validated negative interactors – ypa1 and fft3 (Figure 
3-12). The data indicated that only the tsc2-R1296P allele exhibits synthetic growth defects 
with both ypa1∆ and fft3∆, as previously predicted (Figure 3-13). 
The tuberin GAP domain is well conserved in S. pombe with ~ 45% amino acid 
sequence similarity (Neuman and Henske, 2011; Serfontein et al., 2011). Three disease-
causing missense mutations within this domain are frequent within TSC patients – 
N1643K, N1651S, and P1675L (Jones et al., 1999). Their corresponding orthologous 
mutations in S. pombe (N1191K, N1199S, and P1223L) have been shown to limit nutrient 
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uptake and arginine biosynthesis underlining a unique function of the fission yeast Tsc2p 
GAP domain (van Slegtenhorst et al., 2004). Here, the absence of negative genetic 
interactions involving these mutants in ypa1∆ and fft3∆ backgrounds suggest that these 
mutations do not cause synthetic growth defects that were witnessed when tsc2 was fully 
deleted. Likewise, two other mutant strains outside the Tsc2p GAP domain (G296E and 
R927W) were tested and exhibited normal colony growth. The results, therefore, indicate 
that either these missense mutations in fission yeast do not attribute to loss of Tsc2p 
functions contrary to their orthologous mutations in clinical TSC cases or, that the negative 
interactions between tsc2 and ypa1 or fft3 is conditional on loss of tuberin completely.  
The arginine1743 and arginine1745 sites exist outside the GAP domain near the C- 
terminus of TSC2 (Jones et al., 1999). Surprisingly, mutations in these sites (R1743P and 
R1745Q) abolish the GAP activity of TSC2 and result in the inability to phosphorylate 
downstream p70S6K1 (Li et al., 2004). Patients bearing these mutations therefore suffer 
from the TSC pathology due to an indirect mis-regulation of the tuberin GAP activity (Li 
et al., 2004). In fission yeast, the patient-derived arginine sites are conserved as R1296 and 
R1298 sites. Although, the orthologous tsc2-R1298Q strain was not included in this study, 
the synthetic growth defects exhibited by S. pombe strains bearing the tsc2-R1296P allele 
indicate that this specific site may indeed be important for functional Tsc2p activity. Thus, 
negative interactions between clinically orthologous mutations, and ypa1 or fft3 do not 
appear to be conditional on the complete loss of tuberin. Additionally, the synthetic genetic 
interactions between tsc2-R1296P allele with both ypa1 and fft3 may allude to a broader 
conservation of these negative interactions across TSC patients and warrants a more 
comprehensive analysis of the diverse TSC1 and TSC2 mutations.        
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4.5 Conservation of synthetic interactions 
Previous work has focused on the conservation of genetic interactions across the distantly 
related eukaryotes, S. pombe and S. cerevisiae (Dixon et al., 2008; Roguev et al., 2008). 
The two unicellular yeasts share 30% of the genetic interactome (Dixon et al., 2008; 
Roguev et al., 2008). Given the ~ 400 million years of evolutionary separation between the 
species, this rate of conservation is extensive. Moreover, a large-scale RNAi screen in the 
nematode Caenorhabditis elegans identified a set of ‘hub’ genes that share numerous 
genetic interactions (Lehner et al., 2006). These genes encode highly conserved chromatin 
regulators and their genetic interactions are conserved across species (Lehner et al., 2006). 
Genetic interactions between genes within the same pathway tend to be conserved at a 
higher rate (~ 45%) than those belonging to different processes (~15%) (Ryan et al., 2012). 
The negative interactions examined in this study (among ypa1, fft3, tsc1, and tsc2) are 
presumably involved in ‘between-pathway’ genetic interactions; and such interactions are 
less frequently conserved, at a rate of ~ 15% (compared to the ~35% conservation rate for 
‘within-pathway’ negative interactions) (Ryan et al., 2012).  
Nonetheless, a recent breakthrough using CRISPR-based Tsc2-knockout 
Drosophila spp. cell lines and Tsc2-/- MEFs demonstrated that TSC-specific synthetic 
interactions may indeed be conserved in higher eukaryotes (Housden et al., 2015). Further 
assessment of these interactions in these Tsc2-deficient MEFs was essential to evaluating 
prospective drug targets identified in this study. siRNA knockdowns of the ypa1 and fft3 
homologs – Ppp2r4 and Smarcad1, in the Tsc2-deficient mammalian cells abolished their 
respective gene expression (Figure 3-15). However, only the Ppp2r4 knockdown resulted 
in decreased cellular viability in Tsc2-/- MEFs compared to the wild type cells (Figure 3-
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16). In contrast, the Smarcad1 knockdown had no effects on the survivability of the Tsc2-
deficient MEFs. Altogether, this study provide evidence that, while some genetic buffering 
relationships may be conserved across species, others are not. This phenomenon may be 
explained by the possibility of functional ‘repurposing’ as a result of evolutionary 
divergence and associations of genetic interactions, in addition to the widespread 
conservation among species (Frost et al., 2012). Nonetheless, the results here suggest that 
the Ppp2r4 gene product in humans, PPP2R4, might represent an ideal drug target and, 
thus, may contribute to novel therapeutic strategies to combat the TSC pathology. 
 
4.6 Implications, challenges and future directions 
The understanding of human biology and diseases goes beyond the functions of single 
genes in isolation (Hartman IV et al., 2001). Complex genetic interaction networks are 
involved in a multitude of phenotypic consequences including genetic disorders and 
disease. Genome-wide studies of genetic interactions have led to construction of large-
scale interactomes that provide an opportunity to visualize such complexity (Boone et al., 
2007). In particular, synthetic relationships have played a vital role in the understanding of 
disease mechanisms, drug discovery and novel therapeutic strategies (Nijman, 2011). This 
study sought to utilize the recently developed S. pombe genetic interactome to elucidate 
the molecular pathology of tuberous sclerosis complex and to identify novel disease-
specific drug targets.  
Although the efforts of this study have led to the discovery of a prospective TSC-
specific drug target PPP2R4, limitations remain. First, the isogenic S. pombe strains and 
MEFs used in this study present an inevitable quandary. They are invaluable tools in 
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evaluating the fitness of single mutants with those of the double mutants and help elucidate 
gene buffering relationships (Hartman IV et al., 2001). However, the isogenic background 
of these strains and cell lines often ignores background differences and simplifies the 
complexity within these model systems and thus, limit understanding at a deeper level. 
Also, RNAi tools used in this study offer incomplete transfection, partial gene 
knockdowns, and can have frequent off-target effects leading to false negatives and 
positives (Housden et al., 2015). Therefore, the conservation of the synthetic interactions 
across species requires a more complete examination. Additionally, this study solely 
focused on these interactions in cells mimicking loss-of-function mutations in TSC2 (Tsc2-
/- MEFs). Thus, a comprehensive analysis should look to include investigation in cellular 
contexts bearing TSC1 loss-of-function mutations. Interestingly, Housden et al. (2015) 
developed TSC1 and TSC2 mutant lines in Drosophila spp. and thus, present an opportunity 
for in-depth examination in a different model system.   
Second, the characterization of the negative interactors was limited in the context 
of this work. Fission yeast ypa1 is poorly understood (Goyal and Simanis, 2012) and thus, 
requires extensive cellular and molecular analysis to determine the exact role of the PTPA 
gene product (also known as Ypa1p). In contrast, fft3 is relatively well studied in S. pombe, 
with roles in heterochromatin preservation, transcription, epigenetic inheritance and DNA 
replication (Steglich et al., 2015; Strålfors et al., 2011; Taneja et al., 2017); however, the 
detailed machineries of the Fft3p is yet to be explored. Altogether, a comprehensive study 
of these interactors and their orthologs in humans may help generate useful insights into 
the mechanisms of their corresponding gene products, and such information combined with 
65 
 
the genetic interaction data may help provide a greater understanding of the tuberous 
sclerosis pathogenesis. 
Third, a widespread phenomenon known as NGE can drastically affect large-scale 
genetic interaction data sets (Ben-Shitrit et al., 2012). NGEs can arise from the effects of 
gene deletions on the expression of adjacent genes along the genome (Atias et al., 2015). 
While the mechanism of these effects remains unknown, it is possible that the deletion of 
a given locus alters chromatin structure and/or the regulatory characteristics of adjacent 
loci (Baryshnikova and Andrews, 2012). Recent analysis of the S. cerevisiae genetic 
interactome has revealed that ~ 10% of the scored genetic interactions are affected by NGE 
and the corresponding data sets may be erroneous (Atias et al., 2015). Efforts were made 
to investigate NGE effects on the synthetic interactions observed in this study (Figures 3-
5 and 3-6). Although the data strongly suggest absence of any NGE effects, the analysis is 
not nearly comprehensive enough. Only two adjacent gene deletions were tested for NGE 
effects on each negative interactor (ypa1 and fft3). Thus, the need to increase the number 
of genes included in the NGE studies is apparent. Future annotations of genetic interactions 
may look to utilize recently developed algorithms (Atias et al., 2015; Ben-Shitrit et al., 
2012), that are capable of not only detecting these interactions, but also finding ways to 
correct them.  
Lastly, although the S. pombe genetic interaction data sets are considered large-
scale and encompasses ~ 50% of the genome, it is not entirely complete and suffers from 
limitations. In fact, the more established S. cerevisiae genetic interactome corresponds to 
only ~ 2% of all genetic interactions within a typical mammalian cells (Ryan et al., 2012). 
Thus, the translation of genetic interaction studies from unicellular eukaryotes such as 
66 
 
fission yeast to higher eukaryotes presents difficulty. The presence of multiple tissues, 
numerous cell types and intricate signaling networks in higher eukaryotes can further add 
to the complexity. This obscures the evaluation of any prospective candidates for TSC-
specific therapeutic intervention identified through the fission yeast genetic interactome. 
More complete and diverse analyses are thus required in multiple TSC disease-models in 
addition to the Tsc2-/- MEFs used in this study. Interestingly, patient derived TSC2-
deficient lymphangioleiomyomatosis (LAM) cells have proven a useful model in studying 
tumorigenesis (Li et al., 2014). Furthermore, recent advances in platforms such as shRNA 
knockdown and CRISPR/Cas9-mediated gene knockouts have also made it possible to 
perform synthetic screens for numerous pairs of genes in a large population of cells 
(Beijersbergen et al., 2016). Thus, future studies should aim to utilize these technological 
advances to generate a more comprehensive mammalian genetic interactome from various 
tissues and cell types.  
In conclusion, by combining the genome-wide fission yeast interactome with TSC-
specific genetic networks, this study has helped to shed insights into the molecular 
pathology of tuberous sclerosis complex. In TSC patients, loss of a functional TSC1-TSC2 
heterodimer causes over activation of mTORC1, resulting in increased metabolic and 
oxidative cellular stresses (Beijersbergen et al., 2016). In tumor cells, the rate of cellular 
metabolism increases greatly as the requirement of various cellular processes is enhanced 
(Kroemer and Pouyssegur 2008). Inhibiting key components in the metabolic processes 
can severely impair tumor cells while leaving normal cells relatively unaffected, as the 
tumor-specific cells become highly prone to growth arrest and subsequent cell death 
(Kroemer and Pouyssegur 2008). Hence, targeted inhibition of PPP2R4 might represent an 
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“Achilles’ heel” of the TSC-specific tumors and represents a novel drug target for 
therapeutic intervention. The robustness of this investigation is demonstrated by the 
discovery of a disease-specific drug target utilizing genetic interaction biology 
(Beijersbergen et al., 2016), suggesting that such data sets are invaluable in understanding 
complex human disorders and may aid in future disease-associated inquiries.   
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